Facilitation of emotion regulation with a single dose of escitalopram: A randomized fMRI study

Psychiatry Research - Neuroimaging

Volumn 233, Issue 3, 2015, Pages 451-457

  Outhred, Tim ^a,b   Das, Pritha ^a,b,c   Felmingham, Kim L ^d   Bryant, Richard A ^e   Nathan, Pradeep J ^f,g   Malhi, Gin S ^a,b,c   Kemp, Andrew H ^a,b,c,h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g MONASH UNIVERSITY   (Australia)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antidepressant; Emotion; Emotion regulation; FMRI; Functional connectivity; Serotonin

Indexed keywords

ESCITALOPRAM; PLACEBO; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ACUTE DRUG ADMINISTRATION; ADULT; AMYGDALOID NUCLEUS; ANTIDEPRESSANT ACTIVITY; ARTICLE; BOLD SIGNAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EMOTIONALITY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUMAN EXPERIMENT; INFERIOR FRONTAL GYRUS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; SINGLE DRUG DOSE; TREATMENT RESPONSE; VENTROLATERAL PREFRONTAL CORTEX; ADOLESCENT; AROUSAL; DRUG EFFECTS; EMOTION; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOSTIMULATION; PHYSIOLOGY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AMYGDALA; AROUSAL; CITALOPRAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; PHOTIC STIMULATION; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84950147295     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2015.07.018     Document Type: Article

References (55)

1. Aldao A., Nolen-Hoeksema S., Schweizer S. Emotion-regulation strategies across psychopathology: a meta-analytic review. Clin. Psychol. Rev. 2010, 30:217-237.
2. Alphapharm, 2012. Loxalate: Product Information. Alphapharm, Sydney, Australia.
3. Aron A.R., Robbins T.W., Poldrack R.A. Inhibition and the right inferior frontal cortex. Trends Cogn. Sci. 2004, 8:170-177.
4. Baas D., Aleman A., Kahn R.S. Lateralization of amygdala activation: a systematic review of functional neuroimaging studies. Brain Res. Rev. 2004, 45:96-103.
5. Banks S.J., Eddy K.T., Angstadt M., Nathan P.J., Phan K.L. Amygdala frontal connectivity during emotion regulation. Soc. Cogn. Affect. Neurosci. 2007, 2:303-312.
6. Beck A.T. The evolution of the cognitive model of depression and its neurobiological correlates. Am. J. Psychiatry 2008, 165:969-977.
7. Beck A.T., Rush A.J., Shaw B.F., Emery G. Cognitive Therapy of Depression 1979, Guilford Press, New York.
8. Bennett C.M., Wolford G.L., Miller M.B. The principled control of false positives in neuroimaging. Soc. Cogn. Affect. Neurosci. 2009, 4:417-422.
9. Berking M., Wupperman P. Emotion regulation and mental health: recent findings, current challenges, and future directions. Curr. Opin. psychiatry 2012, 25:128-134.
10. Brühl A.B., Jäncke L., Herwig U. Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants. Psychopharmacology 2011, 216:389-399.
11. Buhle J.T., Silvers J.A., Wager T.D., Lopez R., Onyemekwu C., Kober H., Weber J., Ochsner K.N. Cognitive reappraisal of emotion: A meta-analysis of human neuroimaging studies. Cereb. Cortex 2014, 24:2981-2990.
12. Cisler J., Olatunji B. Emotion regulation and anxiety disorders. Curr. Psychiatry Rep. 2012, 14:182-187.
13. Ehring T., Tuschen-Caffier B., Schnülle J., Fischer S., Gross J.J. Emotion regulation and vulnerability to depression: spontaneous versus instructed use of emotion suppression and reappraisal. Emotion 2010, 10:563-572.
14. Foland L.C., Altshuler L.L., Bookheimer S.Y., Eisenberger N., Townsend J., Thompson P.M. Evidence for deficient modulation of amygdala response by prefrontal cortex in bipolar mania. Psychiatry Res.: Neuroimaging 2008, 162:27-37.
15. Goldin P.R., McRae K., Ramel W., Gross J.J. The neural bases of emotion regulation: reappraisal and suppression of negative emotion. Biol. Psychiatry 2008, 63:577-586.
16. Gotlib I.H., Joormann J. Cognition and depression: current status and future directions. Annu. Rev. Clin. Psychol. 2010, 6:285-312.
17. Gross J.J. Antecedent-and response-focused emotion regulation: divergent consequences for experience, expression, and physiology. J. Personal. Soc. Psychol. 1998, 74:224-237.
18. Gross J.J. Emotion regulation. Handbook of Emotions 2008, 497-512. The Guilford Press, New York. M. Lewis, J.M. Haviland-Jones, L. Feldman Barrett (Eds.).
19. Gross J.J., Thompson R.A. Emotion regulation: conceptual foundations. Handbook of Emotion Regulation 2007, 3-24. The Guilford Press, New York. J.J. Gross (Ed.).
20. Hanson C.S., Outhred T., Brunoni A.R., Malhi G.S., Kemp A.H. The impact of escitalopram on vagally mediated cardiovascular function to stress and the moderating effects of vigorous physical activity: a randomised controlled treatment study in healthy participants. Front. Physiol. 2013, 4.
21. Harmer C.J. Emotional processing and antidepressant action. Curr. Top. Behav. Neurosci. 2012, 14:209-222.
22. Harmer C.J., Goodwin G.M., Cowen P.J. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br. J. Psychiatry 2009, 195:102-108.
23. Kanske P., Heissler J., Schönfelder S., Bongers A., Wessa M. How to regulate emotion? Neural networks for reappraisal and distraction. Cereb. Cortex 2011, 21:1379-1388.
24. Kemp A.H., Gordon E., Rush A.J., Williams L.M. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr. 2008, 13:1066-1086.
25. Kemp A.H., Gray M.A., Silberstein R.B., Armstrong S.M., Nathan P.J. Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. NeuroImage 2004, 22:1084-1096.
26. Kemp A.H., Outhred T., Saunders S., Brunoni A.R., Nathan P.J., Malhi G.S. Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects. Psychopharmacology 2014, 231:2281-2290-10.
27. Kemp A.H., Silberstein R.B., Armstrong S.M., Nathan P.J. Gender differences in the cortical electrophysiological processing of visual emotional stimuli. NeuroImage 2004, 21:632-646.
28. Khan A., Brodhead A.E., Schwartz K.A., Kolts R.L., Brown W.A. Sex differences in antidepressant response in recent antidepressant clinical trials. J. Clin. Psychopharmacol. 2005, 25:318-324.
29. Kret M.E., De Gelder B. A review on sex differences in processing emotional signals. Neuropsychologia 2012, 50:1211-1221.
30. Kroenke K., Spitzer R.L., Williams J.B.W. The PHQ-9. Validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16:606-613.
31. Lang P.J., Bradley M.M., Cuthbert B.N. International affective picture system (IAPS): Affective ratings of pictures and instruction manual 2008, University of Florida, Gainesville, FL, Technical Report A-8.
32. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage 2003, 19:1233-1239.
33. McLaren D.G., Ries M.L., Xu G., Johnson S.C. A generalized form of context-dependent psychophysiological interactions (gPPI): a comparison to standard approaches. NeuroImage 2012, 61:1277-1286.
34. McRae K., Rekshan W., Williams L.M., Cooper N., Gross J.J. Effects of antidepressant medication on emotion regulation in depressed patients: an iSPOT-D report. J. Affect. Disord. 2014, 159:127-132.
35. Mills E.J., Chan A.-W., Wu P., Vail A., Guyatt G.H., Altman D.G. Design, analysis, and presentation of crossover trials. Trials 2009, 10:27.
36. Ochsner K.N., Gross J.J. The cognitive control of emotion. Trends Cogn. Sci. 2005, 9:242-249.
37. Ochsner K.N., Gross J.J. Cognitive emotion regulation: insights from social cognitive and affective neuroscience. Curr. Dir. Psychol. Sci. 2008, 17:153-158.
38. Ochsner K.N., Silvers J.A., Buhle J.T. Functional imaging studies of emotion regulation: a synthetic review and evolving model of the cognitive control of emotion. Ann. N. Y. Acad. Sci. 2012, 1251:E1-24.
39. Outhred T., Das P., Dobson-Stone C., Felmingham K.L., Bryant R.A., Nathan P.J., Malhi G.S., Kemp A.H. The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study. Aust. N. Z. J. Psychiatry 2014, 1-38.
40. Outhred T., Das P., Felmingham K.L., Bryant R.A., Nathan P.J., Malhi G.S., Kemp A.H. Impact of acute administration of escitalopram on the processing of emotional and neutral images: a randomized crossover fMRI study of healthy women. J. Psychiatry Neurosci. 2014, 39:267-275.
41. Outhred T., Hawkshead B.E., Wager T.D., Das P., Malhi G.S., Kemp A.H. Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: implications for differential treatment efficacy. Neurosci. Biobehav. Rev. 2013, 37:1786-1800.
42. Payer D.E., Baicy K., Lieberman M.D., London E.D. Overlapping neural substrates between intentional and incidental down-regulation of negative emotions. Emotion 2012, 12:229-235.
43. Pizzagalli D.A. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011, 36:183-206.
44. Poldrack R.A. Region of interest analysis for fMRI. Soc. Cogn. Affect. Neurosci. 2006, 2:67-70.
45. Poldrack R.A., Fletcher P.C., Henson R.N., Worsley K.J., Brett M., Nichols T.E. Guidelines for reporting an fMRI study. NeuroImage 2008, 40:409-414.
46. Pringle A., Browning M., Cowen P.J., Harmer C.J. A cognitive neuropsychological model of antidepressant drug action. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2011, 35:1586-1592.
47. Roiser J.P., Elliot R., Sahakian B.J. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 2012, 37:117-136.
48. Senn S., D'Angelo G., Potvin D. Carry-over in cross-over trials in bioequivalence: theoretical concerns and empirical evidence. Pharm. Stat. 2004, 3:133-142.
49. Senn S.J. Cross-over trials, carry-over effects and the art of self-delusion. Stat. Med. 1988, 7:1099-1101.
50. Sogaard B., Mengel H., Rao N., Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J. Clin. Pharmacol. 2005, 45:1400-1406.
51. Spitzer R.L., Kroenke K., Williams J.B.W., Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Int. Med. 2006, 166:1092-1097.
52. Townsend J.D., Torrisi S.J., Lieberman M.D., Sugar C.A., Bookheimer S.Y., Altshuler L.L. Frontal-amygdala connectivity alterations during emotion downregulation in bipolar I disorder. Biol. Psychiatry 2013, 73:127-135.
53. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 2002, 15:273-289.
54. World Health Organization The Global Burden of Disease: 2004 update 2008, World Health Organization.
55. Young E.A., Kornstein S.G., Marcus S.M., Harvey A.T., Warden D., Wisniewski S.R., Balasubramani G.K., Fava M., Trivedi M.H., John Rush A. Sex differences in response to citalopram: a STAR*D report. J. Psychiatr. Res. 2009, 43:503-511.